SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
SAB Biotherapeutics (SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:13 AM UTCSAB Biotherapeutics (NASDAQ: SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
... MoreSAB Biotherapeutics (SABS) Reports SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:01 AM UTCSAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced data demonstrating that SAB-185, the companys therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The data were generated by scientists at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).
These in vitro data demonstrate that SAB-185 retains neutralization activity against the... More
